Effects of antiglucocorticoid treatment on 5-HT(1A) function in depressed patients and healthy subjects

Neuropsychopharmacology

Volumn 17, Issue 4, 1997, Pages 246-257

  Price, Lawrence H ^a   Cappiello, Angela ^b   Malison, Robert T ^b   McDougle, Christopher J ^b   Pelton, Gregory H ^b   Schöllnhammer, Günter ^c   Heninger, George R ^b  

^a BROWN UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Bayer Corporation   (Germany)

Author keywords

5 HT(1A) receptor; Antiglucocorticoids; Depression; HPA axis; Ketoconazole; Serotonin

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID ANTAGONIST; GROWTH HORMONE; HYDROCORTISONE; IPSAPIRONE; KETOCONAZOLE; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG CAPSULE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR SENSITIVITY;

ADRENOCORTICOTROPIC HORMONE; ADULT; BODY TEMPERATURE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEEDBACK; FEMALE; GLUCOCORTICOIDS; GROWTH HORMONE; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; KETOCONAZOLE; MALE; MIDDLE AGED; PYRIMIDINES; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 0030805435     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00049-3     Document Type: Article

References (54)

1. Amsterdam JD (1992): Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 16:271-280.
2. 1A agonists in the rat. Neuroendocrinology 50:241-247
3. Barden N, Reul JM, Holsboer F (1995): Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosci 18(1):6-11
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961): An inventory for measuring depression. Arch Gen Psychiatry 4:53-63
5. Biegon A, Rainbow TC, McEwen BS (1985): Corticosterone modulation of neurotransmiter receptors in rat hippocampus: A quantitative autoradiographic study. Brain Res 332:309-314
6. Blier P, de Montigny C (1994): Current advances and trends in the treatment of depression. TIPS 15:220-226
7. 1A receptor mRNA expression. T Neurosci 13:914-923
8. 1A receptor gene expression by dexamethasone. Neuropsychopharmacology 10:215-222
9. Chaouloff F (1993): Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev 18:1-32
10. Chaouloff F (1995): Regulation of 5-HT receptors by corticosteroids: where do we stand? Fundam Clin Pharmacol 9:219-233
11. 1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br J Psychiatry 164:372-379
12. Cutler NR, Hesselink JM, Sramek JJ (1994): A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 18:447-463
13. 1 receptor capacity in raphe-hippocampal system. Neuroendocrinology 42: 513-521
14. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
15. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990): Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418
16. Dinan TG (1994): Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br T Psychiatry 164(3):365-371
17. Dinan TG, Thakore J, O'Keane V (1994): Lowering cortisol enhances growth hormone response to growth hormone releasing hormone in healthy subjects. Acta Physiol Scand 151(3):413-416
18. Engelhardt D, Weber MM (1994): Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Ster Biochem Molec Biol 49(4-6):261-267
19. Fuller RW (1992): The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 13(3):250-270
20. Giustina A, Bussi AR, Deghenghi R, Imbimbo B, Licini M, Poiesi C, Wehrenberg WE (1995): Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J Endocrinol 146:227-232
21. 1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology 15:109-115
22. Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993): An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 8:167-172
23. Haleem DJ (1992): Repeated corticosterone treatment attenuates behavioural and neuroendocrine responses to 8-hydroxy-2-(di-n-prophlamino) tetralin in rats. Life Sci 51:225-230
24. Hamilton M (1959): The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
25. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
26. Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM (1990): Ipsapirone: Evidence for efficacy in depression. Psychopharm Bull 26(2):219-222
27. Holmes MC, Yau JLW, French KL, Seckl JR (1995): The effect of adrenalectomy on 5-hydroxytryptamine and corticosteroid receptor subtype messenger RNA expression in rat hippocampus. Neurosciene 64:327-337
28. Holsboer B (1995): Neuroendocrinology of mood disorders. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, Ltd., pp 957-969
29. Kahn RS, Trestman R, Lawlor BA, Gabriel S, Davidson M, Siever L (1994): Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology 114:155-160
30. Kennett GA, Dickinson DL, Curzon G (1985): Central serotonergic responses and behavioural adaptation to repeated immobilisation: The effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol 119: 143-152
31. Lesch K-P, Rupprecht R, Poten B, Müller U, Söhnle K, Fritze J, Schulte HM (1989): Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry 26:203-205
32. 1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Sci 46:1271-1277
33. 1A receptor responsivity in unipolar depression: Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 28:620-628
34. Maes M, Meltzer HY (1995): The serotonin hypothesis of major depression. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, Ltd., pp 933-944
35. McCormack HM, Home DJd, Sheather S (1988): Clinical applications of visual analogue scales: a critical review. Psychol Med 18:1007-1019
36. McEwen BS (1987): Glucocorticoid-biogenic amine interactions in relation to mood and behavior. Biochem Pharmacol 36(11):1755-1763
37. McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS (1994): Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 14:347-352
38. Meltzer HY, Lowy MT (1987): The serotonin hypothesis of depression. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven Press, pp 513-526
39. Meltzer HY, Maes M (1994): Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 35:316-323
40. 1B receptors in the dorsal hippocampus and cortex of the rat. Neuroendocrinology 55:444-450
41. 1A receptors in rat forebrain. Neuroendocrinology 56:881-888
42. Mobayed M, Dinan TG (1990): Buspirone/prolactin response in post head injury depression. J Affect Dis 19:237-241
43. Moeller FG, Steinberg JL, Fulton M, Kramer G, Petty F (1994): A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 10:75-83
44. Pecknold JC, Luthe L, Scott-Fleury MH, Jenkins S (1993): Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 13:145-149
45. Price LH, Malison RT, McDougle CJ, Pelton GH (1996): Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. CNS Drugs 5: 311-320
46. Schipper T, Tulp MTM, Berkelmens B, Mos J, van der Heyden JAM, Olivier B (1991): Preclinical pharmacology of flesinoxan: A potential anxiolyric and antidepressant drug. Hum Psychopharmacol 6:S53-S61
47. 1A receptor activation by flesinoxan in humans. Neuropsychopharmacology 13:93-104
48. Sonino N (1987): The use of ketoconazole as an inhibitor steroid production. N Engl J Medicine 317(13):812-818
49. Stahl S (1994): 5HT1A receptors and pharmacotherapy. Is serotonin receptor downregulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 30:39-43
50. Stokes PE, Sikes CR (1987): Hypothalamic-pituitary-adrenal axis in affective disorders. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven Press, pp 589-607
51. Thompson K. Coleman ES, Hudmon A, Kemppainen RJ, Soyoola EO, Sartin JL (1995): Effects of short-term cortisol infusion on growth hormone-releasing hormone stimulation of growth hormone release in sheep. Am J Vet Res 56:1228-1231
52. Woods SW, Charney DS, Loke J, Goodman WK, Redmond DE, Heninger GR (1986): Carbon dioxide sensitivity in panic anxiety: ventilatory and anxiogenic response to CO2 in healthy subjects and panic disorder patients before and after alprazolam treatment. Arch Gen Psychiatry 43:900-909
53. 1A receptor is intact in mood disorders. Neuropsychopharmacology 12:263-268
54. Young AH, Dow RC, Goodwin GM, Fink G (1993): The effects of adrenalectomy and ovariectomy on the behavioural and hypothermic responses of rats to 8-hydroxy2-(di-n-propylamino)tetralin (8-OH-DPAT). Neuropharmacology 32:653-657